Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects

References

• EMA (2014). European medicines agency. Xyrem, sodium oxybate, Authorisation details. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000593/human_med_001163.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124
   Google Scholar
• FDA (2017). Food and drug administration. Xyrem ® (sodium oxybate). Prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021196s028lbl.pdf
   Google Scholar
• Busardo F, Kyriakou C, Napoletano S, et al. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur R Med Pharm Sci. 2015;19:4654–4663.
   PubMed Web of Science ®Google Scholar
• EMA. (2017d). European medicines agency. PRAC PSUR assessment report. Sodium oxybate. Procedure no.: EMEA/H/C/PSUSA/00002757/201610
   Google Scholar
• Alcover SmPC. Document available upon request
   Google Scholar
• Nava F, Borroni G, Bosticco E, et al. (2017). Assessment report. Alcover (granules in sachet) and associated names. GHB-Use and Misuse (GUM) study. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Alcover_29_4/WC500241280.pdf
   Google Scholar
• van den Brink W, Addolorato G, Aubin HJ, et al. Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addict Biol. 2018;23:969–986.
   PubMed Web of Science ®Google Scholar
• Skala K, Caputo F, Mirijello A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014;15:245–257.
   PubMed Web of Science ®Google Scholar
• Carter LP, Pardi D, Gorsline J, et al. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009;104:1–10.
   PubMed Web of Science ®Google Scholar
• Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5:365–371.
   PubMed Web of Science ®Google Scholar
• Wang YG, Swick TJ, Carter LP, et al. Sodium oxybate: updates and correction to previously published safety data. J Clin Sleep Med. 2011;7:415–416.
   PubMed Web of Science ®Google Scholar
• Mayer G. The use of sodium oxybate to treat narcolepsy. Expert Rev Neurother. 2012;12:519–529.
   PubMed Web of Science ®Google Scholar
• EMA (2013). European medicines agency. Xyrem INN-Sodium oxybate. . Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000593/WC500057101.pdf
   Google Scholar
• Drakatos P, Lykouras D, D’Ancona G, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80–84.
   PubMed Web of Science ®Google Scholar
• Leone MA, Vigna-Taglianti F, Avanzi G, et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010;CD006266.
   PubMed Web of Science ®Google Scholar
• Rehm J, Guiraud J, Poulnais R, et al. Alcohol dependence and very high risk level of alcohol consumption: a life-threatening and debilitating disease. Addict Biol. 2018;23:961–968.
   PubMed Web of Science ®Google Scholar
• Caputo F, Mirijello A, Cibin M, et al. Novel strategies to treat alcohol dependence with sodium oxybate according to clinical practice. Eur Rev Med Pharmacol Sci. 2015;19:1315–1320.
   PubMed Web of Science ®Google Scholar
• Pharmacovigilance and communicating safety information from the EMA Available from: www.ema.europe.eu
   Google Scholar
• Clinical trial registries operated and maintained by the US NIH ClinicalTrials.gov. Available from: www.clinicaltrials.gov
   Google Scholar
• Clinical trial registries operated and maintained by the EMA. Available from: www.clinicaltrialsregister.eu
   Google Scholar
• Caputo F, Skala K, Mirijello A, et al. Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial. CNS Drugs. 2014b;28:743–752.
   PubMed Web of Science ®Google Scholar
• Caputo F, Skala K, Mirijello A, et al. (2017). Assessment report. Alcover (granules in sachet) and associated names. GATE 1. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Alcover_29_4/WC500241280.pdf
   Google Scholar
• EMA (2017c). European medicines agency. Assessment report. Alcover (granules in sachet) and associated names. Study SMO032/10/03. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Alcover_29_4/WC500241280.pdf
   Google Scholar
• Caputo F, Skala K, Walter H, et al. Sodium oxybate in the prevention of alcohol relapses in alcohol dependent patients (GATE 2 study). Alcohol Alcohol. 2013;48:i33–i34.
   Web of Science ®Google Scholar
• Mattila MJ, Palva E, Seppala T, et al. Actions and interactions with alcohol of drugs on psychomotor skills: comparison of diazepam and gamma-hydroxybutyric acid. Arch Int Pharmacodyn Ther. 1978;234:236–246.
   PubMedGoogle Scholar
• Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet. 1989 **;2:787–789.
   PubMed Web of Science ®Google Scholar
• Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol. 1992;34:231–235.
   PubMed Web of Science ®Google Scholar
• Gallimberti L, Ferri M, Ferrara SD, et al. gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res. 1992;16:673–676.
   PubMed Web of Science ®Google Scholar
• Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol. 1993;45:353–356.
   PubMed Web of Science ®Google Scholar
• Ceccanti M, Attilia ML, Blum K, et al. Gamma-hydroxybutyric acid versus benzodiazepines: a clinical study in chronic alcoholics. Acta Toxicol Ther. 1995;16:231–242.
   Google Scholar
• Cibin M, Zavan V. GHB e trattamento multimodale dell’alcoldipendenza: una esperienza clinica. Alcologia. 1995;7:34.
   Google Scholar
• Di Bello M, Gambassi F, Mugnai L, et al. Gamma-hydroxybutyric acid induced suppression and prevention of alcohol withdrawal syndrome and relief of craving in alcohol-dependent patients. Alcologia. 1995;7:111–118.
   Google Scholar
• Manzato E, Cantiero D, Faccini M. Il GHB nel trattamento del- la dipendenza alcolica in pazienti ambulatoriali (day hospital). Alcologia. 1995;59:36.
   Google Scholar
• Mosti A, Zurla R. L’acido 4-idrossibutirrico (GHB) nella pratica clinica territoriale: analisi preliminare di 100 casi. Alcologia. 1995;7(Suppl. 2):63.
   Google Scholar
• Strepparola G, Alietti M, Mascherpa M, et al. E’ possibile il trattamento del craving? La nostra esperienza con l’acido gamma-idrossibutirrico. Alcologia. 1995;7(Suppl. 2):73.
   Google Scholar
• Vendramin A, Bertuola C. Contribute of the use of GHB alone or with SSRI for the treatment of alcoholism associated with psychopathological disorders. Benfits for a psychotherapeutic integrate approach. Alcologia. 1995;7(Suppl. 2):75.
   Google Scholar
• Zolesi O, Daini L, Capone MR, et al. The use of GHB in anticraving therapy. Preliminary experimental data of its use in alcohol and heroin dependence. In: Tagliamonte A, Maremmani I, editors. Drug addiction and related clinical problems. Vienna: Springer; 1995.
   Google Scholar
• Elsing C, Stremmel W, Grenda U, et al. Gamma-hydroxybutyric acid versus clomethiazole for the treatment of alcohol withdrawal syndrome in a medical intensive care unit: an open, single-center randomized study. Am J Drug Alcohol Abuse. 2009;35:189–192.
   PubMed Web of Science ®Google Scholar
• Avanzi M, Bonomini M, Federici F, et al. Utilità dell’associazione GHB e disulfiram nel trattamento della dipendenza da alcool. Alcologia. 1996;8(2):73.
   Google Scholar
• Ceccanti M, Attilia ML, Ceccanti B, et al. Efficacia di vari protocolli terapeutici nel trattamento della sindrome da astinenza alcolica (SSA). Alcologia. 1996;8(2):72.
   Google Scholar
• Ferrara SD, Tedeschi L, Frison G, et al. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Eur J Clin Pharmacol. 1996;50:305–310.
   PubMed Web of Science ®Google Scholar
• Montesano F, Montesano S, Mellace V, et al. L’uso razionale dell’acido gammaidrossibutirrico (GHB) nei soggetti alcolisti secondo la nostra esperienza. Alcologia. 1997;9(Suppl. 2):73.
   Google Scholar
• Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol. 1996;31:341–345.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Cibin M, Caputo F, et al. Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients. Drug Alcohol Depend. 1998;53:7–10.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Balducci G, Capristo E, et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res. 1999a;23:1596–1604.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Capristo E, Gessa GL, et al. Long-term administration of GHB does not affect muscular mass in alcoholics. Life Sci. 1999b;65:PL191–196.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Caputo F, Capristo E, et al. A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin Neuropharmacol. 1999c;22:60–62.
   PubMed Web of Science ®Google Scholar
• Gallimberti L, Spella MR, Soncini CA, et al. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol. 2000;20:257–262.
   PubMed Web of Science ®Google Scholar
• Moncini M, Masini E, Gambassi F, et al. Gamma-hydroxybutyric acid and alcohol-related syndromes. Alcohol. 2000;20:285–291.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Lamanna F, Tagliamonte A. Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics. J Psychoactive Drugs. 2001;33:135–142.
   PubMed Web of Science ®Google Scholar
• Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, et al. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002;37:67–73.
   PubMed Web of Science ®Google Scholar
• Borgen LA, Okerholm R, Morrison D, et al. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol. 2003;43:59–65.
   PubMed Web of Science ®Google Scholar
• Caputo F, Addolorato G, Lorenzini F, et al. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 2003;70:85–91.
   PubMed Web of Science ®Google Scholar
• Caputo F, Addolorato G, Stoppo M, et al. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol. 2007;17:781–789.
   PubMed Web of Science ®Google Scholar
• Caputo F, Francini S, Stoppo M, et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J Psychopharmacol. 2009;23:883–890.
   PubMed Web of Science ®Google Scholar
• Caputo F, Francini S, Brambilla R, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. Eur Neuropsychopharmacol. 2011;21:450–456.
   PubMed Web of Science ®Google Scholar
• Caputo F, Del Re A, Brambilla R, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: a pilot study. J Psychopharmacol. 2014a;28:23–30.
   PubMed Web of Science ®Google Scholar
• Korninger C, Roller RE, Lesch OM. Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital. Acta Med Austriaca. 2003;30:83–86.
   PubMedGoogle Scholar
• Abanades S, Farre M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006;1074:559–576.
   PubMed Web of Science ®Google Scholar
• Nava F, Premi S, Manzato E, et al. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst. J Psychoactive Drugs. 2006;38:211–217.
   PubMed Web of Science ®Google Scholar
• Nava F, Premi S, Manzato E, et al. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. Am J Drug Alcohol Abuse. 2007;33:379–392.
   PubMed Web of Science ®Google Scholar
• Thai D, Dyer JE, Benowitz NL, et al. GHB and ethanol effects and interactions in humans. J Clin Psychopharmacol. 2006;26:524–529.
   PubMed Web of Science ®Google Scholar
• Stella L, Addolorato G, Rinaldi B, et al. An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacol Res. 2008;57:312–317.
   PubMed Web of Science ®Google Scholar
• Oliveto A, Gentry WB, Pruzinsky R, et al. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol. 2010;21:332–342.
   PubMed Web of Science ®Google Scholar
• Maremmani AG, Pani PP, Rovai L, et al. Long-term gamma-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics. Int J Environ Res Public Health. 2011;8:2816–2827.
   PubMed Web of Science ®Google Scholar
• Gashlin LZ, Sullo D, Lawrence RA, et al. Treatment of narcolepsy with sodium oxybate while breastfeeding: a case report. Breastfeed Med. 2016;11:261–263.
   PubMed Web of Science ®Google Scholar
• Barker EC, Puchowicz M, Letterio J, et al. GHB levels in breast milk of women with narcolepsy with cataplexy treated with sodium oxybate. Sleep Med. 2017;36:172–177.
   PubMed Web of Science ®Google Scholar
• Caputo F, Vignoli T, Tarli C, et al. A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder. Int J Environ Res Public Health. 2016;13. DOI:10.3390/ijerph13030290.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Caputo F, Capristo E, et al. Gamma-Hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol. 2000;20:217–222.
   PubMed Web of Science ®Google Scholar
• Cacciaglia R, Lesch OM, Vivet P (2017). Assessment report. Alcover (granules in sachet) and associated names. GATE 2 study. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Alcover_29_4/WC500241280.pdf
   Google Scholar
• Vree TB, Damsma J, van den Bogert AG, et al. Pharmacokinetics of 4-Hydroxybutyric acid in man, rhesus monkey and dog. In: editor, Frey R. Neue untersuchungen mit Gamma-Hydroxibuttersäure. Anaesthesiologie und intensivmedizin/anaesthesiology and intensive care medicine. Vol. 110. Springer: Berlin, Heidelberg; 1978.
   Google Scholar
• EMA. (2016). European medicines agency. PRAC PSUR assessment report. Sodium oxybate. Procedure no.: EMEA/H/C/PSUSA/00002757/201510. Retrieved Accessed 2018 Apr 10.
   Google Scholar
• EMA (2017a). European medicines agency. Assessment report. Alcover (granules in sachet) and associated names. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Alcover_29_4/WC500241280.pdf
   Google Scholar
• EMA (2017b). European medicines agency. Assessment report. Alcover (granules in sachet) and associated names. Study SMO032/10/01. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Alcover_29_4/WC500241280.pdf
   Google Scholar
• Busardò FP, Jones AW. Interpreting γ-hydroxybutyrate concentrations for clinical and forensic purposes. Clin Toxicol. 2019;57(3):149–163.
   PubMed Web of Science ®Google Scholar
• Pross N, Patat A, Vivet P, et al. Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers. Br J Clin Pharmacol. 2015;80(3):480–492.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs. 2009;18:675–686.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Cibin M, Capristo E, et al. Maintaining abstinence from alcohol with gamma-hydroxybutyric acid. Lancet. 1998;351:38.
   PubMed Web of Science ®Google Scholar